The use of broadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) has been shown to be a promising therapeutic modality in the prevention of HIV infection. Understanding the b12–gp120 binding mechanism under physiological conditions may assist the development of more broadly effective antibodies. In this work, the main conformations and interactions between the receptor-binding domain (RBD) of spike glycoprotein gp120 of HIV-1 and the IgG1-b12 mAb are studied. Accelerated molecular dynamics (aMD) and ab initio hybrid molecular dynamics have been combined to determine the most persistent interactions between the most populated conformations of the antibody–antigen complex under physiological conditions. The resul...
AbstractThe binding of antibodies to the CD4-binding site (CD4bs) of the HIV-1 envelope glycoprotein...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
Structure-guided approaches to HIV-1 vaccine design depend on knowledge of the presentation of neutr...
The use of broadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) has b...
The remarkable diversity, glycosylation and conformational flexibility of the human immunodeficiency...
HIV envelope glycoproteins undergo large-scale conformational changes as they interact with cellular...
Efforts to design an effective antibody-based vaccine against HIV-1 would benefit from understanding...
Degree awarded: Ph.D. Biology. The Catholic University of AmericaThe HIV-1 envelope spike is a trime...
Acquired immunodeficiency syndrome (AIDS) and its causal agent, the human immunodeficiency virus 1 (...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Thesis (Ph.D.)--University of Washington, 2013Due to the impressive diversity of human immunodeficie...
Glycoprotein gp120 is a surface antigen and virulence factor of human immunodeficiency virus 1. Broa...
Monoclonal antibodies b12 and 4E10 are broadly neutralizing against a variety of strains of the huma...
We investigated the interaction between cross-reactive HIV-1 neutralizing human monoclonal antibody ...
AbstractThe binding of antibodies to the CD4-binding site (CD4bs) of the HIV-1 envelope glycoprotein...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
Structure-guided approaches to HIV-1 vaccine design depend on knowledge of the presentation of neutr...
The use of broadly neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) has b...
The remarkable diversity, glycosylation and conformational flexibility of the human immunodeficiency...
HIV envelope glycoproteins undergo large-scale conformational changes as they interact with cellular...
Efforts to design an effective antibody-based vaccine against HIV-1 would benefit from understanding...
Degree awarded: Ph.D. Biology. The Catholic University of AmericaThe HIV-1 envelope spike is a trime...
Acquired immunodeficiency syndrome (AIDS) and its causal agent, the human immunodeficiency virus 1 (...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
Antibodies against the CD4 binding site (CD4bs) on the HIV-1 spike protein gp120 can show exceptiona...
Thesis (Ph.D.)--University of Washington, 2013Due to the impressive diversity of human immunodeficie...
Glycoprotein gp120 is a surface antigen and virulence factor of human immunodeficiency virus 1. Broa...
Monoclonal antibodies b12 and 4E10 are broadly neutralizing against a variety of strains of the huma...
We investigated the interaction between cross-reactive HIV-1 neutralizing human monoclonal antibody ...
AbstractThe binding of antibodies to the CD4-binding site (CD4bs) of the HIV-1 envelope glycoprotein...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
Structure-guided approaches to HIV-1 vaccine design depend on knowledge of the presentation of neutr...